---
title: "Accelerate Diagnostics Inc. Finalizes Asset Sale Amidst Chapter 11 Liquidation Process"
description: "Accelerate Diagnostics, Inc. has finalized an asset sale as part of its Chapter 11 liquidation process. The U.S. Bankruptcy Court confirmed the company's restructuring plan on August 13, 2025. The agr"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/253520059.md"
published_at: "2025-08-18T20:59:37.000Z"
---

# Accelerate Diagnostics Inc. Finalizes Asset Sale Amidst Chapter 11 Liquidation Process

> Accelerate Diagnostics, Inc. has finalized an asset sale as part of its Chapter 11 liquidation process. The U.S. Bankruptcy Court confirmed the company's restructuring plan on August 13, 2025. The agreement with Indaba Capital Management involves selling specific assets and liabilities, with the effective date expected around August 18, 2025. This move is part of the Amended and Restated Asset Purchase Agreement, aimed at implementing the outlined transactions.

Accelerate Diagnostics, Inc., along with its US subsidiary Accelerate Diagnostics Texas, LLC, has reached a significant milestone in its restructuring process. On August 13, 2025, the United States Bankruptcy Court for the District of Delaware confirmed the Second Amended Combined Disclosure Statement and Chapter 11 Plan of Liquidation. The company has entered into an agreement with an affiliate of Indaba Capital Management, L.P., its existing secured noteholder, to sell certain assets and liabilities. This move, part of the Amended and Restated Asset Purchase Agreement, modifies the initial agreement to focus on specific assets. The company anticipates the Plan’s Effective Date to be around August 18, 2025, as it aims to implement the transactions outlined in the Plan. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Accelerate Diagnostics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-079855), on August 18, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [AXDX.US - Accelerate Diagnostics](https://longbridge.com/en/quote/AXDX.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| IDL Diagnostics 在迪拜的 WHX Labs 與 concile 一同參展 | IDL Diagnostics AB (publ) 在迪拜的 WHX Labs 展示了其產品，與 concile 合作，強調了一種平台驅動的方法，以在多種即時檢測設備配置中提供各種生物標誌物。該舉措支持在感染、心臟健康、腫瘤學、激素和慢性疾 | [Link](https://longbridge.com/en/news/276451109.md) |
| Cleo Diagnostics 選擇了下一代 Ella 平台以提供卵巢癌血液檢測 | Cleo Diagnostics 選擇了 Bio-Techne Corporation 的 Ella 平台來推出其卵巢癌血液檢測。Ella 平台提高了檢測的靈敏度和精確度，同時允許對多個生物標誌物進行同時分析。Cleo 於九月份開始使用 E | [Link](https://longbridge.com/en/news/276190725.md) |
| IDL Diagnostics AB（publ）發佈了首席執行官的演示文檔 | IDL Diagnostics AB（公開發行）發佈了首席執行官 Anders Hultman 在 RedEye Fight Cancer 2026 活動上的演講，強調了公司的市場機會和新的戰略優先事項。該演講可供觀看 | [Link](https://longbridge.com/en/news/274501242.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
